

Anti-Nesprin 1 Rabbit Monoclonal Antibody

Catalog # ABO14652

Product Information

Application	WB, IHC, IF, ICC, FC
Primary Accession	Q8NF91
Host	Rabbit
Isotype	Rabbit IgG
Reactivity	Rat, Human, Mouse
Clonality	Monoclonal
Format	Liquid
Description	Anti-Nesprin 1 Rabbit Monoclonal Antibody . Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.

Additional Information

Gene ID	23345
Other Names	Nesprin-1, Enaptin, KASH domain-containing protein 1, KASH1, Myocyte nuclear envelope protein 1, Myne-1, Nuclear envelope spectrin repeat protein 1, Synaptic nuclear envelope protein 1, Syne-1, SYNE1 (HGNC:17089)
Calculated MW	1011086
Application Details	WB 1:500-1:2000 IHC 1:50-1:200 ICC/IF 1:50-1:200 FC 1:50
Source	Eukaryota
Contents	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
Clone Names	Clone: AEFE-19
Immunogen	A synthesized peptide derived from human Nesprin 1
Purification	Affinity-chromatography
Storage	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Protein Information

Name	SYNE1 (HGNC:17089)
Function	Multi-isomeric modular protein which forms a linking network between

organelles and the actin cytoskeleton to maintain the subcellular spatial organization. As a component of the LINC (Linker of Nucleoskeleton and Cytoskeleton) complex involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. May be involved in nucleus- centrosome attachment and nuclear migration in neural progenitors implicating LINC complex association with SUN1/2 and probably association with cytoplasmic dynein-dynactin motor complexes; SYNE1 and SYNE2 may act redundantly. Required for centrosome migration to the apical cell surface during early ciliogenesis. May be involved in nuclear remodeling during sperm head formation in spermatogenesis; a probable SUN3:SYNE1/KASH1 LINC complex may tether spermatid nuclei to posterior cytoskeletal structures such as the manchette.


Cellular Location

Nucleus outer membrane; Single-pass type IV membrane protein; Cytoplasmic side Nucleus. Nucleus envelope. Cytoplasm, cytoskeleton. Cytoplasm, myofibril, sarcomere. Note=The largest part of the protein is cytoplasmic, while its C-terminal part is associated with the nuclear envelope, most probably the outer nuclear membrane. In skeletal and smooth muscles, a significant amount is found in the sarcomeres. In myoblasts, relocated from the nuclear envelope to the nucleus and cytoplasm during cell differentiation


Tissue Location

Expressed in HeLa, A431, A172 and HaCaT cells (at protein level). Widely expressed. Highly expressed in skeletal and smooth muscles, heart, spleen, peripheral blood leukocytes, pancreas, cerebellum, stomach, kidney and placenta. Isoform GSRP-56 is predominantly expressed in heart and skeletal muscle (at protein level).


Images




All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.




All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.




Western blot analysis of Nesprin 1 expression in (1) HeLa cell lysate; (2) RAW264.7 cell lysate.




Immunofluorescent analysis using the Antibody at 1:50 dilution.



Immunofluorescent analysis using the Antibody at 1:50 dilution.




Immunofluorescent analysis using the Antibody at 1:150 dilution.




Immunofluorescent analysis using the Antibody at 1:150 dilution.

Hela



Immunofluorescent analysis using the Antibody at 1:150 dilution.

Hela



Immunofluorescent analysis using the Antibody at 1:500 dilution.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.